In BRCA1-deficient TNBC, PARP inhibitor olaparib activates the cGAS/STING pathway in tumor cells, leading to dendritic cell-dependent CD8+ T cell recruitment and antitumor immunity, with more pronounced effects in HR-deficient models and demonstrated STING pathway dependency (95). Here, CD8A is linked to neoplasm.